medigraphic.com
Revista Médica Sinergia

2020, Number 12

<< Back Next >>

Revista Médica Sinergia 2020; 5 (12)

Overview and new treatments in Beta-thalassemia

Angulo UG, Koss HR, Monge OJM

Language: Spanish
References: 18
Page: 1-15
PDF size: 358.46 Kb.


ABSTRACT

Beta-thalassemia is a congenital disorder generally caused by point mutations in the gene that encodes for the synthesis of globin beta chains, which produces an ineffective erythropoiesis phenomenon, and reduces the half-life of erythrocytes in the most severe forms. However, the classification includes forms of thalassemia of various clinical behaviors; from severe forms to asymptomatic forms. Complications are usually associated with the chronic treatment utilized in this disorder, which includes repeated blood transfusions, amongst others. New therapies seek to reduce the adverse effects associated with transfusions, as well as targeting genetic components of the disease.


REFERENCES

  1. Origa R. β-Thalassemia.Genetics in Medicine [Internet]. 2016 [Citado 27/06/2020];19(6):609-619. https://doi.org/10.1038/gim.2016.173

  2. Shah F, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia, Blood Reviews [Internet]. 2019 [Citado 27/06/2020]; 37:100588. https://doi.org/10.1097/gim.0b013e3181cd68ed.

  3. Cappellini M, Porter J, Viprakasit V, Taher A. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood Reviews [Internet]. 2018 [Citado 27/06/2020];32(4):300-311. https://doi.org/10.1016/j.bj.2015.10.001

  4. Taher A, Karakas Z, Cassinerio E, Siritanaratkul N, Kattamis A, Maggio A et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood [Internet]. 2018 [Citado 29/06/2020];131(2):263-265.https://doi.org/10.1182/blood-2017-06-790121

  5. Hoffman R, Benz E, Silberstein L, Heslop H, Weitz J, Anastasi J et al. Hematology. Philadelphia, PA: Elsevier; 2018.

  6. Khandros E, Kwiatkowski J. Beta Thalassemia. Hematology/Oncology Clinics of North America [Internet] 2019 [Citado 28/06/2020];33(3):339-353.https://doi.org/10.1016/j.hoc.2019.01.003

  7. de Dreuzy E, Bhukhai K, Leboulch P, Payen E. Current and future alternative therapies for betathalassemia major. Biomedical Journal [Internet]. 2016 [Citado 25/06/2020];39(1):24-38. https://dx.doi.org/10.1016%2Fj.bj.2015.10.001

  8. Salah, Naouel Ben, et al. Revisiting Beta Thalassemia Intermedia: Past, Present, and Future Prospects. Hematology [Internet]. 2017 [Citado 1/08/2020];22(20):607-616. https://doi.org/10.1080/10245332.2017.1333246

  9. Hoffbrand A, Steensma, P. Essential Hematology. Philadelpia, PA: Wiley Blackwell, 2019.

  10. Cappellini M, Viprakasit V, Taher A, Georgiev P, Kuo K, Coates T et al. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. New England Journal of Medicine. [Internet] 2020 [Citado 29/06/2020] ;382(13):1219-1231. https://doi.org/10.1056/nejmoa1910182

  11. Betts, Marissa, et al. Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-Dependent β-Thalassemia. Clinical Therapeutics [Internet]. 2020 [Citado 29/06/2020]; 42(2):322-337.https://doi.org/10.1016/j.clinthera.2019.12.003

  12. Soni S. Novel and innovative approaches for treatment of β-thalassemia. Pediatric Hematology Oncology Journal [Internet]. 2017 [Citado 29/06/2020];2(4):121-126.https://doi.org/10.1016/j.phoj.2017.11.153

  13. El-Beshlawy, Amal, and Mona El-Ghamrawy. Recent Trends in Treatment of Thalassemia. Blood Cells, Molecules, and Diseases [Internet]. 2019 [Citado 29/06/2020]; 79:53-59. https://doi.org/10.1016/j.bcmd.2019.01.006

  14. Thein S. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells, Molecules, and Diseases [Internet]. 2018 [Citado 29/06/2020]; 70:54-65.https://dx.doi.org/10.1016%2Fj.bcmd.2017.06.001

  15. Richard F, Lier J, Roubert B, Haboubi T, Göhring U, Dürrenberger F. Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers. American Journal of Hematology [Internet]. 2019 [Citado 29/06/2020];95(1):68-77.https://dx.doi.org/10.1002%2Fajh.25670

  16. Karponi G, Zogas N. Gene Therapy for Beta-Thalassemia: Updated Perspectives. The Application of Clinical Genetics [Internet]. 2019 [Citado 29/06/2020]; 12:167-180. https://dx.doi.org/10.2147%2FTACG.S178546

  17. Boulad, Farid, et al. Gene Therapy and Genome Editing.” Hematology/Oncology Clinics of North America [Internet]. 2018 [Citado 29/06/2020]; 32(2):329-342. https://doi.org/10.1016/j.hoc.2017.11.

  18. Wienert, Beeke, et al. Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies. Trends in Genetics [Internet]. 2018 [Citado 29/06/2020]; 34(12): 927-940. https://doi.org/10.1016/j.tig.2018.09.004




2020     |     www.medigraphic.com